Summary
- The problem
- Release waits for the end of the batch, and QA then reconstructs the case from separate batch, laboratory and quality records.
- Seal’s approach
- The release case is built while the batch runs. Each requirement has an owner, a source and a recorded outcome, so the open blocker is visible.
- What changes
- QA records exactly what it decided and on what evidence, and the decision carries into inventory status, market eligibility and certificates.
- Where to start
- One difficult batch: the release procedure, its batch record and the open items. Book a demo.
1Build the release case before the batch is finished.
Release work starts with the requirements for this product, site and destination. Seal brings the executed batch record, material genealogy, laboratory evidence and quality reviews into one case. Each requirement has an owner, a source and a recorded outcome. Teams can see which work is complete, which evidence is missing and which decision is holding the batch.
Begin with your approved release procedure. Define the population, applicable specification, manufacturing instructions, sampling plan, review roles and market conditions. Keep the effective versions with the case. A reviewer should be able to explain why a requirement applies to this batch without reconstructing the plan from separate files.
Evidence
- Manufacturing (met)Batch record and genealogy
- QC laboratory (met)Approved results
- Quality (met)Deviations and impact
- Inventory (met)Released within scope
- Certificate (met)From approved results
- Market M2 (met)Eligible
- Market M1 (not met)Awaiting acknowledgement
1.1Why teams choose Seal for batch release
When release waits for the end of the batch, QA collects the batch record, laboratory results and quality events from separate systems, checks them page by page and records a disposition. Seal keeps the release requirements, their evidence and the open blockers on the platform where the batch, tests and investigations run, so the case assembles as the work happens. A revised release procedure applies to later decisions, and each earlier decision keeps the requirements and evidence it was made on.
2Give each blocker a source and an owner.
B-071 has three reviewed laboratory results and an unresolved hold-time exception. Its release case connects the 52-minute observation, the 45-minute instruction limit, the deviation and the required product-impact assessment. The quality reviewer can follow the issue to its source; the production reviewer can see the conclusion needed to complete manufacturing review.
The same approach applies to a missing signature, preliminary result, unapproved substitution or incomplete source-data review. Keep the reason, responsible role, linked evidence and next action together. A review queue should tell the team what to do next while keeping every required check visible, including those already complete.
3Review the evidence that was true at execution.
Manufacturing review needs the instruction version used, actual values, calculations, material lots, equipment, people, times, corrections and signatures. Each batch must be tested against its final specifications before release, so laboratory review needs sample identity, the applicable specification and method, suitability, reportable results and their approval.¹ A preliminary passing value does not satisfy a requirement for an approved result.
Equipment, cleaning and personnel checks concern the time and purpose of use. A balance being calibrated today does not establish its state when the batch ran. Keep the relevant eligibility evidence with the recorded use, and link any later investigation to the batches it may affect. Preserve original results and invalidation history when a replacement result is generated.
Balance calibration
4Review as evidence arrives, with a clear path for changes.
Manufacturing, QC and QA can review completed evidence while later activities continue. Retain each review’s scope, source versions and outcome, so the final reviewer can distinguish work already assessed from new information. Configure which corrections, new results or linked deviations require reassessment, then verify that path before use.
For short-shelf-life products, include expected result availability, review handoffs and the latest decision time in the plan. The team can work on the actual critical path. Any conditional or exceptional release path still requires the applicable approved procedure, evidence and authorised decision; the schedule alone does not resolve a missing requirement.
5Record precisely what QA decided.
Once the impact assessment is approved and manufacturing review is complete, the case is ready for the authorised release role. The disposition records the defined batch population, quantity, presentation, evidence reviewed, rationale, conditions, signature meaning and effective time. Completing the preceding reviews does not make that decision; it remains with the quality unit.²
A release, rejection, restriction or further-evaluation outcome must carry its own scope. When an authorised amendment is needed, preserve the previous decision and the reason for the change. A reviewer returning later should be able to reconstruct the evidence considered and the decision made at that point, including any approved outstanding conditions.
- Decision
- Release
- Scope
- Batch B-071, defined presentation
- Evidence
- Four requirements, reviewed versions
- Condition
- Market M1 awaits acknowledgement
- Signed
- QA, as the release decision
6Carry the decision into stock, markets and certificates.
A manufacturer disposition and permission to distribute to a destination can differ. Once released, B-071 is eligible for Market M2 while Market M1 still awaits authority acknowledgement. Keep the market condition visible alongside the signed disposition. Configure inventory and distribution controls to apply the intended population and destination scope.
Prepare the certificate of analysis from the approved product, specification and reportable result versions. Retain certificate review, issue and replacement history. Reconcile the disposition, stock transition, applicable market gates, certificate and required notifications before closing the case. Each downstream record should lead back to the decision that supports it.
7Start with one difficult batch.
Bring an approved release procedure and a representative batch with a real review problem. Scope the source systems, release requirements and responsible teams. Use Neil to prepare the evidence index and proposed review work; have the team review the configuration and verify the release path against its intended use.
Prove the awkward cases as well as the completed case: a preliminary result, a changed reviewed record, an unresolved impact assessment, an unauthorised completion attempt and a destination that remains blocked after QA disposition. Agree which record owns each decision and how stock and certificates consume it. That gives the first workflow a concrete acceptance boundary.
Connect batch execution, QC laboratory work, deviation assessment, inventory and certificates of analysis around the same release case.
References
- 121 CFR 211.165, Testing and release for distribution: each batch must be tested for conformance to final specifications, including identity and strength of each active ingredient, prior to release. eCFR
- 221 CFR 211.22, Responsibilities of quality control unit: a quality control unit must have the responsibility and authority to approve or reject components, in-process materials, packaging, labelling and drug products, and to review production records. eCFR
AConnected across Seal
BCapabilities
| Capability | What it covers |
|---|---|
| Release requirement planning | Resolve execution, testing, quality, equipment, training, data-review, market, certificate and approval obligations from the effective product state. |
| Evidence and population resolution | Link each obligation to the reviewed version of its source record and to the batches, samples, events, people, assets and documents in scope. |
| Exception-based review | Route missing, failed, stale, changed or judgement-dependent requirements to reviewers while keeping the full review population visible. |
| Concurrent review | Review completed evidence during execution with source-version snapshots. Configure and verify reassessment when relevant source data changes. |
| QA disposition | Sign release, rejection, restriction, reprocessing or other decisions for a precise population with conditions, rationale, evidence and segregation of duties. |
| Market eligibility | Keep manufacturer disposition distinct from authority release, label, import testing, serialisation and other destination-specific distribution gates. |
| CoA provenance | Populate reviewed certificates from approved specifications and reportable results, with field-level source traceability and replacement history. |
| Release reconciliation | Close only after obligations, exceptions, decisions, market gates, inventory transitions, certificates and approved open controls agree. |
CConnected records
DQuestions and answers
Does Seal replace MES, LIMS and QMS for batch release?
Not necessarily. The release case can draw on records from existing validated systems or from Seal modules. It resolves source evidence to requirements and retains what QA reviewed, without making every connected system the same system.
What does review by exception mean?
Configured checks verify rule-based requirements and route unresolved items to reviewers. The full population stays visible: teams can see each rule run, included record, evidence version, exclusion, stale item and manual judgement, not only the flagged items.
Can QA review before manufacturing is complete?
Yes. Completed evidence can be reviewed during execution, with each review’s scope and source versions retained. Configure and verify which later changes require reassessment. Final disposition still requires the complete configured evidence set.
How are deviations and OOS results handled?
They remain linked to their operation, sample, result, evidence, investigation and product-impact decision. Closing an investigation does not itself release a batch; QA records how its approved conclusion affects the defined release population.
Does a QA-released batch become distributable everywhere?
Not necessarily. Market eligibility can also depend on authority lot release, local testing, the registered specification, approved labelling, import or serialisation requirements. These states stay distinct and can be configured as distribution gates.
How are equipment and training checked?
Eligibility is evaluated at the time and purpose of use against effective qualification, calibration, maintenance, cleaning, curriculum, practical qualification, expiration and restriction records. Today’s status is not used as retroactive proof.
Can Seal generate a CoA?
Yes, once the configured prerequisites are met. Product, batch, market, specification, reportable results, statements and disposition populate controlled fields with their provenance. Review, signature, delivery, correction and replacement follow the approved workflow.
What supports short-shelf-life products?
The release plan shows when evidence is expected, the latest decision time, handoffs, missing data and contingencies. Concurrent review reduces avoidable waiting, while conditional paths still follow approved product- and market-specific procedures.
Can a release decision be changed?
An authorised amendment or reversal creates a new signed decision linked to the prior one. It identifies the affected population and inventory, and starts the required notifications and controls, and the earlier decision is retained.
What should an implementation prove first?
Take one difficult lot from release planning through execution and testing evidence, including a deviation or OOS result. Continue through concurrent review, point-in-time equipment and training checks, QA disposition, a market-specific gate, the inventory transition, the CoA and final reconciliation.
